Edition:
United Kingdom

Foamix Pharmaceuticals Ltd (FOMX.OQ)

FOMX.OQ on NASDAQ Stock Exchange Global Market

3.76USD
23 Jan 2019
Change (% chg)

$0.07 (+1.90%)
Prev Close
$3.69
Open
$3.70
Day's High
$3.82
Day's Low
$3.68
Volume
51,010
Avg. Vol
148,474
52-wk High
$7.55
52-wk Low
$3.22

Select another date:

Wed, Nov 7 2018

Foamix's treatment for common skin condition meets late-stage trial goals

Foamix Pharmaceuticals Ltd said on Wednesday its experimental foam treatment for rosacea, a common skin condition that causes acne-like bumps and redness on the face, met the main goals of two late-stage clinical trials.

Foamix's treatment for common skin condition meets late-stage trial goals

Nov 7 Foamix Pharmaceuticals Ltd said on Wednesday its experimental foam treatment for rosacea, a common skin condition that causes acne-like bumps and redness on the face, met the main goals of two late-stage clinical trials.

Foamix acne drug meets main goals in late-stage trial, shares surge

Foamix Pharmaceuticals Ltd said on Tuesday that its lead drug treating moderate-to-severe acne met the main goals of its third late-stage study, sending its shares up 57 percent in extended trading.

UPDATE 1-Foamix acne drug meets main goals in late-stage trial, shares surge

Sept 11 Foamix Pharmaceuticals Ltd said on Tuesday that its lead drug treating moderate-to-severe acne met the main goals of its third late-stage study, sending its shares up 57 percent in extended trading.

Foamix Pharma's acne drug meets main goals in late-stage trial

Sept 11 Foamix Pharmaceuticals Ltd said on Tuesday that its drug treating moderate-to-severe acne met the main goals of its third late-stage study.

Select another date: